Sep 05, 2019 / NTS GMT
Yoshito Nakanishi - Chugai Pharmaceutical Co., Ltd. - Specialist, Entrectinib Lifecycle Leader, Project & Lifecycle Management Unit
Let me start. My name is Nakanishi, and I'm Rozlytrek Lifecycle Leader. First, I would like to explain what is Rozlytrek. It is a small molecule tyrosine kinase inhibitor that selectively blocks kinases, including TRK family. Its generic name is entrectinib. Its target is TRK kinase family that consists of TRKA, TRKB and TRKC. Its target cancer is NTRK fusion-positive solid tumors. Please note that proteins are called TRKA, B and C, whereas their genes are called NTRK1, 2 and 3.
Next is history of development. Initially, clinical trials for Rozlytrek were started by an Italian company called Nerviano, then an American company called Ignyta in San Diego continued the development. Clinical trials by Ignyta showed very high efficacy for NTRK-positive solid tumors, so Breakthrough Therapy designation was granted in the U.S., and PRIME designation was granted in Europe. Also, it received the SAKIGAKE designation, thanks to the assistance by Dr. Yoshino who is here today.
Chugai Pharmaceutical Co Ltd Information Meeting on Rozlytrek Transcript
Sep 05, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers